<DOC>
	<DOCNO>NCT00256750</DOCNO>
	<brief_summary>The purpose study learn Belatacept provide protection organ rejection follow kidney transplantation avoid toxic effect standard immunosuppressive medication kidney damage . Effects kidney function patient survival well drug safety also study .</brief_summary>
	<brief_title>Belatacept Evaluation Nephroprotection Efficacy First-line Immunosuppression ( BENEFIT )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>The subject recipient live donor decease donor kidney transplant . Male Female , 18 old First time recipient , PRA &gt; 50 % retransplantation PRA &gt; 30 % . If retransplantation , previous graft loss due acute rejection . Positive cross match . Subject receive extended criterion donor ( ECD ) organ For Longterm extension studySubjects complete three year study treatment ( Week 156 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>